常规时段
					
										
  | 
									
										
  | 
									
										
  | 
									
										
  | 	
										
										
  | 
									
									
									
								||||||||||||
  | 
									
										
  | 
								
									
										
  | 
									
										
  | 
									
										
  | 
								
										
  | 
									
										
  | 
									
										
  | 
								
| 价值评估 | 
| 
										 盈利(现时/预测) 
										
												-6.06/-0.06										 
									 | 
								
| 
										 企业价值 
										
											22.45M										 
									 | 
								
| 资产负债 | 
| 
											 每股账面净值 
											
												0.05											 
										 | 
									
| 现金流量 | 
| 
											 现金流量率 	
											
																					--											 
										 | 
									
| 损益表 | 
| 
											 收益 
											 
													0											 
										 | 
									
| 
											 每股收益 
											
												--											 
										 | 
									
| 
	   					 同行比较 
	   					
	   				 | 
	   			||||||||||||||||||||||||||||||||||||||||||||||||
  | 
		   		
 
																报价延迟最少15分钟:2025/11/03 19:59 EST
														同行比较之报价最少15分钟延迟
											| 
						 业务概览 
					 | 
				|||
| Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors. | 

				
						
 3.2														
